N-terminal propeptide of type 3 collagen-based sequential algorithm can identify high-risk steatohepatitis and fibrosis in MAFLD.
Liang-Jie TangGang LiMohammed EslamPei-Wu ZhuSui-Dan ChenHoward Ho-Wai LeungOu-Yang HuangGrace Lai-Hung WongYu-Jie ZhouMorten KarsdalDiana Julie LeemingPei JiangCong WangHai-Yang YuanChristopher D ByrneGiovanni TargherJacob GeorgeVincent Wai-Sun WongMing-Hua ZhengPublished in: Hepatology international (2022)
The new sequential algorithm reliably identifies liver inflammation and fibrosis in MAFLD, making it easier to exclude low-risk patients and recommending high-risk MAFLD patients for clinical trials and emerging pharmacotherapies.